Schrödinger (SDGR) +71% Surge: AI Drug Discovery Momentum Builds
Key Takeaways
- Schrödinger (SDGR) shares rose roughly 71% over the 30 days ending September 17, 2026, climbing from about $17.67 to $30.24 and reaching a new 52-week high.
- The rally reflects growing investor enthusiasm for AI-driven drug discovery, the launch of the Bunsen AI co-scientist, and the formation of Tectora Therapeutics.
- On September 17 alone, the stock added 26.37% on trading volume roughly seven times its recent average.
- Over the trailing three months, the shares have advanced more than 90%, extending a sustained uptrend off the 52-week low of $10.95.
- Schrödinger remains unprofitable on a trailing-twelve-month basis, and the stock now trades well above the average analyst price target.
Schrödinger's Platform and Market Position
Schrödinger, Inc. develops a physics-based computational platform used to discover and optimize novel molecules for drug development and materials design. The company operates two segments: a Software business that licenses its platform to pharmaceutical, biotechnology, and materials-science customers, and a Drug Discovery segment that advances a portfolio of collaborative and proprietary programs. Built on more than three decades of research and development, the platform combines physics-based molecular simulation with machine learning, a capability that has positioned Schrödinger at the intersection of computational chemistry and artificial intelligence. In July 2026, the company launched the early-access version of Bunsen, an agentic AI co-scientist designed to automate complex molecular-discovery workflows. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow the stock for its recurring software revenue, its AI positioning, and the optionality of its drug-discovery collaborations and company-creation strategy.
Stock Price Performance Over the Last 30 Days and Quarter
Over the 30 days ending September 17, 2026, SDGR rose from a closing price of $17.67 on August 18 to $30.24, a gain of approximately 71%. The move accelerated sharply in the final sessions of the period: the shares advanced 9.1% on September 14, 12.05% on September 15, and 26.37% on September 17, when the stock closed at a 52-week high just below the session high of $30.41.
The quarterly picture is even stronger. Over the trailing three months, the stock has climbed more than 90%, recovering from roughly $15.76 in mid-June. The shares now trade well above their 50-day moving average of about $17.99 and their 200-day moving average of about $14.96, underscoring the breadth and persistence of the uptrend across both short- and longer-term time frames.
What Drove the 30-Day Rally
The most immediate catalyst was the September 9 announcement that Schrödinger co-founded Tectora Therapeutics with New Enterprise Associates and RA Capital Management. Tectora closed a $55 million Series A and took on two early-stage immunology and inflammation programs from Schrödinger in exchange for an equity stake plus eligibility for future milestones and royalties. Although specific economic terms were not disclosed, the structure validated Schrödinger's company-creation model and extended the rally that followed.
Broader AI sentiment also played a central role. Reports that U.S. health regulators were considering new roles focused on technology and artificial intelligence lifted AI-enabled healthcare names, while Schrödinger's own Bunsen launch and its strategic agreement with Bristol Myers Squibb (BMY) to deploy Bunsen across its research organization reinforced the company's positioning as a beneficiary of the AI drug-discovery theme. Earlier in the period, second-quarter results reported on August 5 showed an earnings and revenue beat, with annual contract value growing 27% year over year.
Drivers Behind the Quarterly Advance
The multi-month advance reflects a broader re-rating of Schrödinger from a loss-making software and pipeline story toward a validated AI drug-discovery platform. Central to that narrative is the company's track record of company creation: Schrödinger has generated more than $750 million in returns from collaborations, co-invented drugs, and co-founded companies, including the acquisition of Ajax Therapeutics by Eli Lilly (LLY) in a deal valued at up to $2.3 billion. Schrödinger received a cash payment tied to that transaction, along with a $10 million collaboration milestone recognized in the second quarter.
Operating momentum also supported the trend. Hosted-software adoption accelerated toward 47% of software revenue, new products such as predictive toxicology began contributing to annual contract value, and management raised full-year drug-discovery revenue guidance. These developments, combined with a rebound in biotech funding and investor appetite for AI applications in life sciences, underpinned the stock's steady climb from its 52-week low.
Factors to Watch for SDGR Going Forward
Several factors will shape the outlook for SDGR. First, investors will monitor the company's third-quarter results, with particular attention to annual contract value growth, hosted-software adoption, and any update on Bunsen deployments. Second, the company's existing partnerships remain important: Novartis (NVS) has indicated it is reprioritizing its portfolio, and the economic implications of any changes to that collaboration may become clearer in the third quarter. Third, the sustainability of the AI drug-discovery trade will depend on tangible commercial progress rather than sentiment alone, including disclosed terms for the Tectora stake, new collaboration agreements, and clinical or preclinical milestones. Finally, with the stock trading well above the average analyst price target, valuation and short interest remain considerations for investors evaluating the risk-reward balance.
AI Tools for Momentum and Volatility Strategies
In my research on names like this, I often review Tickeron's Trending AI Robots page to explore curated, AI-powered trading bots. It highlights top-performing strategies across different timeframes and risk profiles, which can complement manual analysis when evaluating momentum-driven opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
SDGR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SDGR turned positive on September 15, 2026. Looking at past instances where SDGR's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on SDGR as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +30.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where SDGR advanced for three days, in 212 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 139 of 173 cases where SDGR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
SDGR broke above its upper Bollinger Band on September 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SDGR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.441) is normal, around the industry mean (7.463). P/E Ratio (46.778) is within average values for comparable stocks, (44.990). SDGR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.509). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (6.835) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of chemical simulation software solutions to pharmaceutical industry.
Industry ServicestotheHealthIndustry
Advertisement